Baseline polymorphisms found in patients infected with non-clade BHIV-1 do not affect outcome to HAART

Baseline polymorphisms found in patients infected with non-clade BHIV-1 do not affect outcome to HAART

Bibliografske podrobnosti
Main Authors:	Frater, A, Galpin, S, Beardall, A, Clarke, JR, Ariyoshi, K, Weber, J, McClure, M
Format:	Journal article
Izdano:	2000

Podobne knjige/članki

Impact of baseline polymorphisms in RT and protease on outcome of highly active antiretroviral therapy in HIV-1-infected African patients.
od: Frater, A, et al.
Izdano: (2001)

Comparative response of African HIV-1-infected individuals to highly active antiretroviral therapy.
od: Frater, A, et al.
Izdano: (2002)

The impact of HIV-1 subtype on the clinical response on HAART.
od: Frater, J
Izdano: (2002)

Performance of two commercially available sequence-based HIV-1 genotyping systems for the detection of drug resistance against HIV type 1 group M subtypes.
od: Beddows, S, et al.
Izdano: (2003)

Nephrotoxicity of HAART
od: Robert Kalyesubula, et al.
Izdano: (2011-01-01)

HIV-1 resistance genotyping by sequencing produces inconsistent results for mixed viral populations.
od: Frater, A, et al.
Izdano: (2000)

Simple detection of point mutations associated with HIV-1 drug resistance.
od: Frater, A, et al.
Izdano: (2001)

Association between secondary mutations in human immunodeficiency virus type 1 protease and therapeutic outcome.
od: Frater, J, et al.
Izdano: (2002)

Neurodegeneration in the HAART era
od: Brew Bruce J
Izdano: (2010-05-01)

HAART and the liver: friend or foe?
od: Pineda JA, et al.
Izdano: (2010-03-01)

The R region found in the human foamy virus long terminal repeat is critical for both Gag and Pol protein expression.
od: Russell, R, et al.
Izdano: (2001)

Differential susceptibility of retroviruses to nucleoside analogues.
od: Rosenblum, L, et al.
Izdano: (2001)

HIV/HCV coinfection, HAART, and liver-related mortality.
od: Sabin, C, et al.
Izdano: (2004)

Found footage and magnetization of affection
od: Carlos Adriano
Izdano: (2015-12-01)

Control of viral replication after cessation of HAART
od: Buvé Anne, et al.
Izdano: (2011-02-01)

Lipodystrophy syndrome in HIV-infected children on HAART
od: Steve Innes, et al.
Izdano: (2009-12-01)

Tolerability of antiretroviral therapy (HAART) in elderly age
od: Celesia B M
Izdano: (2010-05-01)

HAART and ATT in the HIV-positive patient with tuberculosis
od: Zi Z Jhiens, et al.
Izdano: (2012-01-01)

Better quality of life with neuropsychological improvement on HAART
od: Hall Colin D, et al.
Izdano: (2006-02-01)

Assessing the effect of HAART on change in quality of life among HIV-infected women
od: Hu Zheng, et al.
Izdano: (2006-03-01)

Anemia and risk factors in HAART naïve and HAART experienced HIV positive persons in south west Ethiopia: a comparative study.
od: Lealem Gedefaw, et al.
Izdano: (2013-01-01)

Association of oral candidal carriage, candidal density and CD4 count among normal, HIV patients with HAART and without HAART
od: Shahabe Saquib Abullais, et al.
Izdano: (2022-06-01)

Mutagenically separated PCR assay for rapid detection of M41L and K70R zidovudine resistance mutations in CRF01_AE (subtype E) human immunodeficiency virus type 1.
od: Myint, L, et al.
Izdano: (2002)

Identification of clade-defining single nucleotide polymorphisms for improved rabies virus surveillance
od: Ankeet Kumar, et al.
Izdano: (2024-12-01)

Intensive Care Usage by HIV-Positive Patients in the HAART Era
od: L. Turtle, et al.
Izdano: (2011-01-01)

Genetic Markers Associated to Dyslipidemia in HIV-Infected Individuals on HAART
od: Rosmeri K. Lazzaretti, et al.
Izdano: (2013-01-01)

Treatment of CMV Retinitis with Intravitreal Ganciclovir in the HAART Era
od: Robert J Campbell, et al.
Izdano: (2001-01-01)

HAART, ocular opportunistic infections, ocular malignancies, and uveitis
od: Rujittika Mungmunpuntipantip, et al.
Izdano: (2024-01-01)

Causes of hypercalcemia in people living with HIV in the HAART era
od: Arkom Nongnuch, et al.
Izdano: (2020-10-01)

Neurologic complications of HIV in the HAART era: where are we?
od: Monica M. Gomes da Silva

HAART (Highly Active Anti-Retroviral Therapy) : An overview
od: Praful Pande, et al.
Izdano: (2014-01-01)

Low Genetic Polymorphism in the Immunogenic Sequences of <i>Rhipicephalus microplus</i> Clade C
od: Ismail Zeb, et al.
Izdano: (2022-11-01)

Prevalence and predictors of dyslipidemia among HAART treated and HAART naive HIV positive clients attending Debre Tabor Hospital, Debre Tabor, Ethiopia
od: Anemut Tilahun, et al.
Izdano: (2022-11-01)

Prevalence of Hypertension in HIV/AIDS Patients on Highly Active Antiretroviral Therapy (HAART) Compared with HAART-Naïve Patients at the Limbe Regional Hospital, Cameroon.
od: Christian Akem Dimala, et al.
Izdano: (2016-01-01)

Does HAART efficacy translate to effectiveness? Evidence for a trial effect.
od: Prema Menezes, et al.
Izdano: (2011-01-01)

Immunotoxin complementation of HAART to deplete persisting HIV-infected cell reservoirs.
od: Edward A Berger, et al.
Izdano: (2010-06-01)

Determinants of survival following HIV-1 seroconversion after the introduction of HAART.
od: Porter, K, et al.
Izdano: (2003)

Protective HLA class I alleles are associated with reduced immune activation and fibrinolysis in individuals with primary HIV infection
od: Hamlyn, E, et al.
Izdano: (2010)

2228 The association of gastrointestinal symptoms and hypertension in persons living with HIV on HAART
od: Kierra R. Butler, et al.
Izdano: (2018-06-01)

Gregory the Great
od: McClure, J, et al.
Izdano: (1979)